

事務連絡

平成 27 年 12 月 14 日

各都道府県衛生主管部（局）薬務主管課 御中

厚生労働省医薬・生活衛生局審査管理課

「かぜ薬等の製造販売承認基準の英訳について」の一部改正について

一般用医薬品のうち、かぜ薬等の製造販売の承認基準（通知）については、「かぜ薬等の製造販売承認基準の英訳について」（平成 27 年 9 月 29 日付け事務連絡、以下「事務連絡」という。）において、その英訳を示してきたところですが、鼻炎用内服薬の製造販売承認基準については、「鼻炎用内服薬の製造販売承認基準について」の一部改正について」（平成 27 年 12 月 14 日付け薬生発 1214 第 2 号厚生労働省医薬・生活衛生局長通知）により改正したことから、事務連絡別添 4 を添付のとおりに改正したのでお知らせいたします。

記

別添	通知名	発出年月日等
4	鼻炎用内服薬の製造販売承認基準について	平成 27 年 3 月 25 日付け薬食発 0325 第 23 号 平成 27 年 12 月 14 日付け薬生発 1214 第 2 号 一部改正



Provisional Translation  
from Japanese Original

Mar 25, 2015  
Notification PB No.23  
(Dec 14, 2015, Partial Revision)

## The Standards for Marketing Approval of Oral Remedies for Rhinitis

### 1. Scope of Oral Remedies for Rhinitis

The scope of remedies subject to these standards covers oral medicines (with the exception of cold remedies, anti-allergic agents, remedies based on Kampo medicine\* formulas) formulated with the intent of relieving symptoms of rhinitis.

\*Kampo medicine is traditional Japanese medicine.

### 2. Approval Standards

The approval standards for oral remedies for rhinitis are as follows.

For remedies not conforming to these standards, data concerning the efficacy and safety and reasons justifying the combination should be submitted; the preparation in question will be reviewed based on these data.

#### (1) Types of Active Ingredients

- a. Table 1 shows the types of active ingredients that may be used.
- b. The active ingredients that must be used are those listed in Column I of Table 1.
- c. Active ingredients from different columns of Table 1 may be combined with each other, unless otherwise stipulated.
- d. When active ingredients from Column I, Column III, or Column IV are to be combined, only 1 ingredient from each column may be used.
- e. When active ingredients from Column II of Table 1 are combined, up to 2 active ingredients from Group 1 may be used, but only 1 from Group 2 may be used. However, the combination of dl-methylephedrine hydrochloride and l-methylephedrine hydrochloride or that of pseudoephedrine hydrochloride and pseudoephedrine sulfate is not permitted.
- f. When the active ingredients from Group 2 in Column I of Table 1 are combined, only formulas other than oral solutions and syrups can be used. They should not be combined concomitantly with the active ingredients from Column V.

#### (2) Quantities of Active Ingredients

- a. The maximum daily doses of individual active ingredients should be those given in Table 1, unless otherwise indicated. The maximum single dose is 1/3rd of the maximum daily dose.  
However, the maximum single dose of oral solutions and syrups is 1/6th of the maximum daily dose.
- b. When active ingredients from Column IV of Table 1 are combined with those of Group 1 in Column II, the maximum daily dose of ingredients from Column IV should be half of those specified in Table 1.
- c. When 2 or more active ingredients from Column II of Table 1 are combined, the sum of the values obtained by dividing the amount of each active ingredient by the respective maximum daily dose should not exceed 2.

- d. The lower limit of the daily dose for each active ingredient from Column I of Table 1 is half of its maximum daily dose.
- e. The lower limit of the daily dose for each active ingredient from Columns II and IV of Table 1 is 1/5th of its maximum daily dose.
- f. The lower limit of the daily dose for each active ingredient from Columns III and V of Table 1 is 1/10th of its maximum daily dose.
- g. The daily dose of the active ingredients from Group 2 in Column I of Table 1 should be limited to 4 mg.

(3) Dosage Forms

The dosage forms are capsules, granules, pills, powders, tablets, oral solutions (with the exception of elixirs; hereinafter the same should apply), and syrups.

(4) Dosage and Administration

- a. Dosage and administration are to be 3 times a day, in principle. The times of administration and intervals between them should be clearly indicated, but intervals between doses should be 4 or more hours. For oral solutions and syrups, taking them up to 6 times a day is acceptable, but when dosing is 6 times a day, each dose is to be taken at approximately 4-hour intervals, in principle.
- b. Dosage for infants less than 3 months of age is not approved.
- c. For formulas containing promethazine hydrochloride or promethazine methylenedisalicylate from Group 1 in Column I of Table 1 and the active ingredients from Group 2 in Column I, dosage for children under 15 years of age is not approved.
- d. For formulas containing pseudoephedrine hydrochloride or pseudoephedrine sulfate from Group 1 in Column II of Table 1, dosage for children under 3 years of age is not approved.
- e. For hard capsules, and soft capsules, pills, and tablets larger than 6 mm in diameter, dosage for children under 5 years of age is not approved.
- f. For soft capsules, pills, and tablets of a diameter of 6 mm or less, dosage for children under 3 years of age is not approved.
- g. The maximum daily dose for children under 15 years of age is that obtained by multiplying the maximum daily doses listed in Table 1 by the coefficient for the respective age groups in Table 2.
- h. The maximum single dose for oral solutions and syrups is 10 mL.

(5) Indications

The indications are to be within the following scope:

Relief of the following symptoms due to acute rhinitis, allergic rhinitis or sinusitis; sneezing, runny nose (excessive nasal discharge), stuffy nose, watery eyes, sore throat, dull headache (heaviness in the head).

(6) Packaging Units

The maximum volume of containers for oral solutions and syrups is a 4-day supply at the maximum daily dose.

Table 1

## Active Ingredients and Maximum Daily Doses

Category		Active ingredient		Maximum daily dose
Column I	Group 1	Alimemazine tartrate		5mg
		Isothipendyl hydrochloride		12mg
		Iproheptine hydrochloride		150mg
		Difeterol hydrochloride		90mg
		Tripelenamine hydrochloride		100mg
		Thonzylamine hydrochloride		50mg
		Methodilazine hydrochloride		8mg
		Chlorpheniramine maleate		12mg
		d-Chlorpheniramine maleate		6mg
		Carbinoxamine diphenyldisulfonate		7.5mg
		Diphenylpyraline hydrochloride		12mg
		Diphenylpyraline teoclate		4.5mg
		Diphenhydramine hydrochloride		75mg
		Diphenhydramine salicylate		75mg
		Diphenhydramine tannate		75mg
		Triprolidine hydrochloride		6mg
		Promethazine hydrochloride		15mg
		Promethazine methylenedisalicylate		40mg
		Carbinoxamine maleate		16mg
	Group 2	Mequitazine		4mg
Column II	Group 1	Phenylephrine hydrochloride		30mg
		Pseudoephedrine hydrochloride		180mg
		Pseudoephedrine sulfate		180mg
		dl-Methylephedrine hydrochloride		110mg
		l-Methylephedrine hydrochloride		110mg
		Methoxyphenamine hydrochloride		150mg
	Group 2	Datura Extract		as total alkaloids 0.6mg
		Belladonna (Total) Alkaloids		0.6mg
		Belladonna Extract		60mg
		Isopropamide iodide extract		7.5mg
		Scopolia Extract		60mg
Column III	Group 1	Glycyrrhizinic acid and its salts		as glycyrrhizinic acid 200mg
	Group 2	Glycyrrhiza	Extract (converted to the crude drug amount)	Powder
			5g	1.5g
Column IV	Caffeine and sodium benzoate		300mg	
	Caffeine hydrate		300mg	
	Anhydrous caffeine		300mg	
Column V		Extract (converted to the crude drug amount)	Powder	

	Schizonepeta Spike	3g	-
	Asiasarum Root	3g	-
	Ginger	3g	1g
	Magnolia Flower	3g	-
	Peucedanum Root	3g	-
	Angelica Dahurica Root	3g	1g

Table 2

Range of ages and coefficients

Age	Coefficient
15 years of age and over	1
11 to under 15 years of age	2/3
7 to under 11 years of age	1/2
3 to under 7 years of age	1/3
1 to under 3 years of age	1/4
6 months to under 1 year of age	1/5
3 months to under 6 months of age	1/6